OCS vs OKYO

Oculis Holding AG vs OKYO Pharma Limited — Valuation Comparison 2026

OCS

Biotechnology
Oculis Holding AG
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$29.65
Last close
Models
8/13
Active
VS

OKYO

Biotechnology
OKYO Pharma Limited
Quality
1.7
out of 10
Value Trap
Price
$1.71
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType OCS Fair ValueOCS Upside OKYO Fair ValueOKYO Upside
Bayesian DCF Intrinsic $8.55 -71.2% $0.45 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.25 -92.4% $0.66 -61.1%
PWERM Option-Based $28.45 -4.1% $1.04 -38.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OCS vs OKYO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OCS vs OKYO — Which Stock Is More Undervalued?

OCS scores higher with a 3.8/10 quality rating vs OKYO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oculis Holding AG (OCS) and OKYO Pharma Limited (OKYO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OCS currently trades at $29.65 with a QOC of 3.8/10, while OKYO trades at $1.71 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).